VALNEVA Announces Publication of its Registration
Post# of 301275
Valneva Announces Publication of its Registration Document
Lyon (France), March 23, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, announces today the publication of its 2016 Registration Document ("Document de Référence"), filed with the French Financial Market Authority ("Autorité des Marchés Financiers") under the filing number D.17-0205 on March 22, 2017.
Valneva's 2016 Registration Document includes the Company's 2016 Annual Financial Report, notably comprising:
- the Separate Financial Statements (including the amount of fees paid to the Statutory Auditors);
- the Consolidated Financial Statements;
- the Report by the Chairman of the Supervisory Board on the preparation and organization conditions of the Supervisory Board and the internal control procedures implemented by the Company, together with the corresponding Auditors' Report.
In addition, the 2016 Registration Document contains the Company's 2016 Management Report, including a description of Valneva's share buy-back program and the Group's Corporate Social Responsibility Report.
It is available on the Company's corporate website ( www.valneva.com/en/investors-media/registration-document ) and on the AMF website ( www.amf-france.org ). A hard copy of the document may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.
About Valneva SE
Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva's portfolio includes two commercial vaccines for travelers: IXIARO ® /JESPECT ® indicated for the prevention of Japanese encephalitis and DUKORAL ® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66 ® vaccine production cell line, IC31 ® adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com .
| Contacts Valneva SE Laetitia Bachelot Fontaine Head of Investor Relations & Corporate Communications T +33 (0)2 2807 1419 M +33 (0)6 4516 7099 investors@valneva.com | Nina Waibel Corporate Communications Specialist T +43 1206 201 149 M +43 6768 455 6719 Communications@valneva.com |
(0)
(0)